SEC Form 4 · accession 0001140361-17-001760
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Abdun-Nabi
Officer — President and CEO · Director
Period of report
Jan 10, 2017
Accepted (ET)
Jan 12, 2017 · 9:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2016 | J | 1,979 | $0.00 | A | 172,945 | D | |
| Common StockF2 | Aug 1, 2016 | J | 3,032 | $0.00 | A | 175,977 | D | |
| Common StockF3 | Aug 1, 2016 | J | 3,419 | $0.00 | A | 179,396 | D | |
| Common StockF4 | Jan 10, 2017 | M | 38,006 | $14.51 | A | 217,402 | D | |
| Common StockF4,F5 | Jan 10, 2017 | S | 28,240 | $31.2782 | D | 189,162 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F6,F8 | $14.51 | Aug 1, 2016 | J | 3,662 | A | — | Mar 8, 2017 | Common Stock | 3,662 | 41,668 | D |
| Stock Option (Right to buy)F7,F8 | $14.51 | Jan 10, 2017 | M | 38,006 | A | — | Mar 8, 2017 | Common Stock | 38,006 | 3,662 | D |
Explanation of responses
- F1In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017.
- F2In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.
- F3In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.
- F4The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive.
- F6Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award.
- F7Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off.
- F8The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.